• Title/Summary/Keyword: anticancer agent

Search Result 464, Processing Time 0.023 seconds

Cytotoxic Effects on HL-60 Cells of Myosin Light Chain Kinase Inhibitor ML-7 Alone and in Combination with Flavonoids

  • Lee, Joong-Won;Kim, Yang-Jee;Choi, Young-Joo;Woo, Hae-Dong;Kim, Gye-Eun;Ha, Tae-Kyung;Lee, Young-Hyun;Chung, Hai-Won
    • Toxicological Research
    • /
    • v.25 no.4
    • /
    • pp.181-188
    • /
    • 2009
  • Uncontrolled cell growth and increased cell proliferation are major features of cancer that are dependent on the stable structure and dynamics of the cytoskeleton. Since stable cytoskeleton structure and dynamics are partly regulated by myosin light chain kinase (MLCK), many current studies focused on MLCK inhibition as a chemotherapeutic target. As a potent and selective MLCK inhibitor, ML-7 [1-(5-iodonaphthalene-1-sulfonyl)-1 H-hexahydro-1,4-diazapine hydrochloride] is a promising candidate for an anticancer agent, which would induce apoptosis as well as prevents invasion and metastasis in certain types of cancer cells. This study assessed cytotoxic effects of ML-7 against HL-60 cells and therapeutic efficacy of ML-7 as a potential antileukemia agent. Trypan-blue exclusion assays showed dose- and time- dependent decreases in ML-7 treated HL-60 cells (p<0.05). Comet assays revealed a significant increase in DNA damage in HL-60 cells after treatment with $40{\mu}M$ ML-7 for 2h. Sub-G1 fractions, analyzed by flow cytometry increased in a dose-dependent manner, suggesting that ML-7 can induce apoptotic cell death in HL-60 cells. ML-7 was selectively cytotoxic towards HL-60 cells; not affecting normal human lymphocytes. That selective effect makes it a promising potential anti-leukemia agent. In addition, anticancer efficacy of ML-7 in combination with flavonoids (genistein or quercetin) or anticancer drugs (cisplatin or Ara-C) against HL-60 cells was assessed. Combination of ML-7 with flavonoids increased the anti-cancer effect of ML-7 to a greater extent than combination with the anticancer drugs. This implies that ML-7 in combination with flavonoids could increase the efficacy of anticancer treatment, while avoiding side effects cansed by conventional anticancer drug-containing combination chemotherapy.

Anticancer Effect of Paedoksans for Oral Squamous Cell Carcinoma and Malignant Pleural Mesothelioma (패독산류의 구강편평세포암종 및 악성중피종에 대한 항암 활성)

  • Oh, Ha-Na;Kim, Hyun-Jung;Chae, Jung-Il;Shim, Jung-Hyun;Yoon, Goo
    • Korean Journal of Pharmacognosy
    • /
    • v.48 no.3
    • /
    • pp.213-218
    • /
    • 2017
  • In order to search for anticancer agent as therapy of oral squamous cell carcinoma (OSCC) and malignant pleural mesothelioma (MPM) from Korean traditional prescriptions, we selected 58 traditional prescriptions based on a review of the Korean traditional medicine books. Among the selected traditional prescriptions, only water extracts of paedoksan (敗毒散) showed relatively good cytotoxicity at the concentration of $50{\mu}g/ml$. Additionally, we evaluated cytotoxicity for various paedoksans and each herbal ingredient in paedoksans. The root of Anthriscus sylvestris exhibited more cytotoxic effect than any other ingredients in paedoksans. Bioactivity-guided fractionation of the MC layer of Anthriscus sylvestris led to the isolation of deoxypodophyllotoxin (DPT). DPT exhibited dose-dependently significant cytotoxicity against OSCC and MPM cell with nM range. Therefore, DPT from A. sylvestris might be a potential candidate as an effective anticancer therapeutic agent for OSCC and MPM.

A Case Report of Partial Remission of Renal Cell Carcinoma with Multiple Liver Metastases Treated with Korean Herbal Medicine in Conjunction with Targeted Anticancer Therapy Afinitor (한약치료와 표적항암요법(아피니토)을 병행하여 부분 관해 된 신세포암 간전이 환자 1례)

  • Chang, Sung-Hwan;Park, Ji-Hye;Yoo, Hwa Seung
    • Journal of Korean Traditional Oncology
    • /
    • v.22 no.2
    • /
    • pp.13-24
    • /
    • 2017
  • Objectives: The purpose of this study is to report the effect of Korean Herbal Medicine (KHM) on a Renal Cell Carcinoma with multiple liver metastases patient. Methods: One renal cell carcinoma with multiple liver metastases patient was treated by KHM in conjunction with targeted anticancer agent (Afinitor). The effect of KHM was measured by scanning with Computed Tomography (CT), Blood Test, Visual Analogue Scale (VAS) and Eastern Cooperative Oncology Group scale. Results: Multiple hepatic tumors were reduced after the treatment during 5 months (Partial Remission, PR). As treatment was performed, complications induced by targeted anticancer agent (Afinitor) were alleviated. Conclusions: This case provides us a possibility that Korean Herbal Medicine offers potential benefits for renal cell carcinoma with multiple liver metastases patient.

Base Specificity for DNA Interstrand Cross-Linking Induced by Anticancer Agent Bizelesin

  • Lee, Chong-Soon;Myung, Pyung-Keun;Gibson, Neil W.
    • Archives of Pharmacal Research
    • /
    • v.19 no.3
    • /
    • pp.191-196
    • /
    • 1996
  • Bizelesin is a promising novel anticancer agent which is known to alkylate N3 of adenine to induce DNA interstrand cross-links (ISC) with in $5^I-TAATTA\; and\; 5^I-TAAAAAA$. We have investigated the base specificity for DNA ISC induced by bizelesin using oligomers containing the cross-linkable sequence $5^I-TAATTA\; and\; 5^I-TAAAAAA$. in which "N" was either A, C, G, or T. An analysis of denaturing polyacrylamide gel showed that bizelesin is able to induce DNA ISC in the duplex oligomer containing sequences $5^I-TAATTA\; and\; 5^I-TAAAAAA$. The formation of interstrand crosslinking did not occur in the sequences $5^I-TAATTA\; and\; 5^I-TAAAAAA$. DNA strand cleavage assay to determine the cross-linking site within $5^I-TAATTA$sequence showed that bizelesin alkylates guanine. These results demonstrate that bizelesin is able to induce DNA ISC at guanine but not at cytosine or thymine. In addition, guanine adducts have been found to be susceptible to DNA strand cleavage by exposure to hot piperidine. The extent of DNA strand cleavage, however, was not 100% efficient in either neutral pH buffer or hot piperidine.

  • PDF

Preparation of Curcumin-loaded Dequalinium Emulsion for Mitochondria-targeted Drug Delivery (미토콘드리아 표적 약물 전달을 위한 curcumin 함유 dequalinium emulsion 제조)

  • Hye Won Park;Joon Sig Choi
    • Applied Chemistry for Engineering
    • /
    • v.35 no.5
    • /
    • pp.451-457
    • /
    • 2024
  • This study focused on the development of a dequalinium-containing oil-in-water (O/W) emulsion (DQE) system for delivering the mitochondria-targeted anticancer agent, curcumin. Dequalinium is a mitochondria-targeting agent with known antibacterial and anticancer properties, and its efficacy in treating malaria has been previously recognized. Structurally, dequalinium is amphiphilic, comprising hydrophobic methylene and hydrophilic quinaldinium groups. In this study, curcumin, a well-documented anticancer and antioxidant compound, was incorporated into the oil phase of an emulsion using dequalinium as the emulsifier. Castor oil, chosen for its biodegradability and high stability in the body, was used as the oil phase in this study. The curcumin-loaded DQE was prepared using ultrasonic sonication followed by homogenization. The morphology and size distribution of the emulsion particles, as assessed using nanoparticle analysis, atomic force microscopy, and transmission electron microscopy, ranged from 100-200 nm. Confocal microscopy confirmed the efficient mitochondrial targeting ability of DQE in HeLa cells. These findings establish the DQE system as a promising drug delivery platform with efficient mitochondrial targeting capabilities and the potential to encapsulate water-insoluble drugs.

Revisit to Unfulfilled Premise of Arylsulfonylimidazolidinones as Anticancer Agent

  • Hung, Dang-The;Lee, Jee-Hyun;Cho, Soo-Hyun;Hong, Chang-Yong;Jeong, Shin-Wu;Jeon , Ki-Wan;Lee, Sung-Bae;Choi, Whan-Geun;Jung, Sang-Hun
    • Proceedings of the PSK Conference
    • /
    • 2002.10a
    • /
    • pp.344.3-345
    • /
    • 2002
  • For the development of novel anticancer agent. we have designed. synthesized. and tested novel 4-phenyl-1(N)-arylsulfonylimidazolidinones. As a result. much more potent cytotoxicities of these compounds against the various cancer cell lines than those of doxorubicin were demonstrated. Elaboration on aryl motif on sulfonyl moiety led us to find highly potent 4-phenyl-1-(N-acylindoline-5-sulfonyl)imidazolidinones. Among them, 4-phenyl-l- [N-(p-aminobenzoyl)indoline-5-sulfonyl]imidazolidinone (PA) was proved to have good pharmacological profile. (omitted)

  • PDF

Cancer Chemopreventive Potential of Procyanidin

  • Lee, Yongkyu
    • Toxicological Research
    • /
    • v.33 no.4
    • /
    • pp.273-282
    • /
    • 2017
  • Chemoprevention entails the use of synthetic agents or naturally occurring dietary phytochemicals to prevent cancer development and progression. One promising chemopreventive agent, procyanidin, is a naturally occurring polyphenol that exhibits beneficial health effects including anti-inflammatory, antiproliferative, and antitumor activities. Currently, many preclinical reports suggest procyanidin as a promising lead compound for cancer prevention and treatment. As a potential anticancer agent, procyanidin has been shown to inhibit the proliferation of various cancer cells in "in vitro and in vivo". Procyanidin has numerous targets, many of which are components of intracellular signaling pathways, including proinflammatory mediators, regulators of cell survival and apoptosis, and angiogenic and metastatic mediators, and modulates a set of upstream kinases, transcription factors, and their regulators. Although remarkable progress characterizing the molecular mechanisms and targets underlying the anticancer properties of procyanidin has been made in the past decade, the chemopreventive targets or biomarkers of procyanidin action have not been completely elucidated. This review focuses on the apoptosis and tumor inhibitory effects of procyanidin with respect to its bioavailability.

Pharmacokinetic Scaling of SJ-8029. a Novel Anticancer Agent Possessing Microtubule and Topoisomerase Inhibiting Activities. by Species-Invariant Time Methods

  • Kim, Dong-Hwan;Shin, Beom-Soo;Cho, Chang-Youn;Park, Si-Koung;Chung, Sung-Gan;Cho, Eui-Hwan;Lee, Sun-Hwan;Joo, Jeong-Ho;Kwon, Ho-Suk
    • Proceedings of the PSK Conference
    • /
    • 2002.10a
    • /
    • pp.422.1-422.1
    • /
    • 2002
  • This study examined the pharmacokinetic disposition of SJ-8029. a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities. in mice. rats. rabbits and dogs after i.v. administration. The serum concentration-time curves of SJ-8029 were best described by tri-exponential equations in all these animal species. The mean CI. $V_{ss}$ and $t_{1/2}$ were 0.3 L/h. 0.1 Land 63.2 min in mice. 1.5 L/h. 1.6 Land 247.7 min in rats. 13.8 L/h. 39.6 Land 245.9 min in rabbits. and 29.2 L/h. 44.6 Land 117.4 min in dogs. respectively. (omitted)

  • PDF